- Ritedose has partnered with Tenpoint Therapeutics to manufacture YUVEZZI, an FDA-approved ophthalmic solution for presbyopia.
- The collaboration leverages Ritedose’s sterile Blow-Fill-Seal CDMO capabilities to support commercial production and supply.
The Ritedose Corporation has entered into a contract manufacturing agreement with Tenpoint Therapeutics to produce YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, an FDA-approved treatment for presbyopia. The product is described as the first dual-agent eye drop approved for this indication.
Ritedose will manufacture the therapy using its sterile Blow-Fill-Seal (BFS) production capabilities, which are designed for unit dose ophthalmic and respiratory solutions. The partnership is intended to support commercial readiness and ensure supply for the product’s launch.
Tenpoint Therapeutics selected Ritedose based on its experience in sterile ophthalmic and respiratory manufacturing, with more than 25 years of operational history. The company stated that partnering with an established CDMO supports supply chain reliability and production quality for the therapy.
The agreement reflects the importance of validated sterile manufacturing in the ophthalmic market, where regulatory requirements and quality standards are critical. The collaboration aims to support the availability of YUVEZZI to patients at scale.
“Our leading aseptic manufacturing capabilities make Ritedose the ideal partner to deliver safe and effective doses of YUVEZZI to patients.”
Jody Chastain, President and CEO of Ritedose
